Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Contingent Consideration (Details)

v3.24.2.u1
Fair Value Measurements - Contingent Consideration (Details) - USD ($)
3 Months Ended 6 Months Ended
Jan. 11, 2024
Jun. 21, 2023
Mar. 31, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 03, 2024
Dec. 31, 2023
Fair Value Measurements              
Exarafenib milestone contingent consideration (Note 4)       $ 2,922,000      
Contingent consideration under RPAs, AAAs and CPPAs       3,000,000     $ 7,000,000
Payments of consideration under RPAs, AAAs and CPPAs       37,000,000 $ 14,650,000    
Kinnate              
Fair Value Measurements              
Exarafenib milestone contingent consideration (Note 4)       2,900,000      
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement              
Fair Value Measurements              
Payments of consideration under RPAs, AAAs and CPPAs   $ 5,000,000.0          
Contingent consideration, high-end of range       0      
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones              
Fair Value Measurements              
Contingent consideration under RPAs, AAAs and CPPAs   1,000,000.0 $ 0 0   $ 0 $ 1,000,000.0
Payments of consideration under RPAs, AAAs and CPPAs $ 1,000,000.0   $ 1,000,000.0 $ 1,000,000.0      
Contingent consideration, high-end of range   $ 5,000,000.0